# αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

> **NCT05373147** · EARLY_PHASE1 · UNKNOWN · sponsor: **Shanghai Mengchao Cancer Hospital** · enrollment: 21 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** αPD1-MSLN-CAR T cells

## Key facts

- **NCT ID:** NCT05373147
- **Lead sponsor:** Shanghai Mengchao Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-30
- **Primary completion:** 2023-02
- **Final completion:** 2023-08
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2022-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05373147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05373147, "αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05373147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*